[A23-103] Sacubitril/valsartan (heart failure, children and adolescents) – Addendum to Commission A23-56

Last updated 07.12.2023

Project no.:
A23-103

Commission:
Commission awarded on 24.10.2023 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Heart and circulation

Indication:

Children and adolescents aged 1 year or older with symptomatic chronic heart failure with left ventricular systolic dysfunction

Result of dossier assessment:

Unchanged after addendum: Added benefit not proven

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

DOI:

https://dx.doi.org/10.60584/A23-103

Federal Joint Committee (G-BA)

2023-12-07 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form